Reproducibility of Serologic Assays for Influenza Virus A (H5N1)
, Alan Heath, Diane Major, Robert W. Newman, Katja Hoschler, Wang Junzi, Jacqueline M. Katz, Jerry P. Weir, Maria C. Zambon, and John M. Wood
Author affiliations: University of Leicester, Leicester, UK (I. Stephenson); National Institute for Biological Standards and Controls, Potters Bar, UK (A. Heath, D. Major, R.W. Newman, J.M. Wood); Health Protection Agency, Colindale, UK (K. Hoschler, M.C. Zambon); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (J.M. Katz); Food and Drug Administration, Rockville, Maryland, USA (J.P. Weir); National Institute for the Control of Pharmaceutical and Biological Products, Beijing, People’s Republic of China (W. Junzhi)
Figure 1. Intralaboratory reproducibility showing proportion (%) of replicate assays differing by >2-fold (A, B) and >4-fold (C, D) by horse hemagglutination-inhibition and neutralization assays for each participating laboratory for all serum samples (A, C) and postvaccination serum samples (B, D). Laboratory 11 did not return hemagglutinin-inhibition result.
Page created: November 01, 2010
Page updated: November 01, 2010
Page reviewed: November 01, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.